RS60933B1 - Derivati tetrahidroizohinolina - Google Patents
Derivati tetrahidroizohinolinaInfo
- Publication number
- RS60933B1 RS60933B1 RS20201139A RSP20201139A RS60933B1 RS 60933 B1 RS60933 B1 RS 60933B1 RS 20201139 A RS20201139 A RS 20201139A RS P20201139 A RSP20201139 A RS P20201139A RS 60933 B1 RS60933 B1 RS 60933B1
- Authority
- RS
- Serbia
- Prior art keywords
- methyl
- dihydroisoquinolin
- dichlorophenyl
- ethanone
- chloro
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14188174 | 2014-10-08 | ||
| PCT/EP2015/073053 WO2016055479A1 (en) | 2014-10-08 | 2015-10-06 | Tetrahydroisoquinoline derivatives |
| EP15775688.3A EP3204359B1 (en) | 2014-10-08 | 2015-10-06 | Tetrahydroisoquinoline derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS60933B1 true RS60933B1 (sr) | 2020-11-30 |
Family
ID=51790569
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20201139A RS60933B1 (sr) | 2014-10-08 | 2015-10-06 | Derivati tetrahidroizohinolina |
Country Status (18)
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108884077A (zh) * | 2016-02-25 | 2018-11-23 | 阿森纽荣股份公司 | 糖苷酶抑制剂 |
| CA3018352A1 (en) | 2016-04-13 | 2017-10-19 | Ucb Biopharma Sprl | Tetrahydroisoquinoline derivatives |
| CN107698433A (zh) * | 2017-09-12 | 2018-02-16 | 潍坊滨海石油化工有限公司 | 苯乙酸的制备方法 |
| DK3717025T3 (da) | 2017-12-01 | 2021-11-22 | UCB Biopharma SRL | Billeddannende midler |
| TWI725408B (zh) * | 2018-04-20 | 2021-04-21 | 美商美國禮來大藥廠 | 多巴胺d1受體正向異位調節劑 |
| US12358890B2 (en) | 2019-07-01 | 2025-07-15 | UCB Biopharma SRL | Substituted tetrahydroisoquinoline derivative as a D1 positive allosteric modulator |
| IL289314B2 (en) * | 2019-07-01 | 2025-09-01 | UCB Biopharma SRL | Tetrahydroisoquinoline derivative is transformed as a positive allosteric modulator d1 |
| KR20230014706A (ko) * | 2020-04-24 | 2023-01-30 | 더 리전츠 오브 더 유니버시티 오브 캘리포니아 | Nurr1 수용체 조절제 및 이의 용도 |
| CN111943930B (zh) * | 2020-08-25 | 2022-11-01 | 南京三元阳普医药科技有限公司 | Lasmiditan的合成工艺 |
| JP7591138B2 (ja) * | 2020-10-07 | 2024-11-27 | イーライ リリー アンド カンパニー | ドーパミンｄ１受容体ポジティブアロステリック調節因子としてのフェニル－３，４－ジヒドロイソキノリン－２（１ｈ）－イル－エタン－１－オン誘導体 |
| EP4267555A1 (en) * | 2020-12-03 | 2023-11-01 | UCB Biopharma SRL | Octahydroisoquinolinyl derivatives |
| CN116685308A (zh) * | 2020-12-18 | 2023-09-01 | Ucb生物制药有限责任公司 | 无定形固体分散体 |
| JP7777589B2 (ja) | 2020-12-18 | 2025-11-28 | ユーシービー バイオファルマ エスアールエル | ジヒドロイソキノリニル誘導体 |
| WO2022129356A1 (en) * | 2020-12-18 | 2022-06-23 | UCB Biopharma SRL | Prodrugs of 2-(3,5-dichloro-1-methyl-indazol-4-yl)-1-[(1s,3r)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl]ethanone |
| LT4263517T (lt) * | 2020-12-18 | 2025-01-10 | UCB Biopharma SRL | Pakeistasis tetrahidroizochinolino darinys kaip d1 teigiamas alosterinis moduliatorius |
| JP2024509448A (ja) | 2021-03-08 | 2024-03-01 | イーライ リリー アンド カンパニー | 幻覚及び認知症に関連する精神病の治療におけるメビダレン及び他のｄ１陽性アロステリックモジュレーターの使用 |
| BR112023018196A2 (pt) | 2021-03-09 | 2023-12-12 | Lilly Co Eli | Uso de mevidalen e outros moduladores alostéricos positivos d1 para retardar a progressão da doença de parkinson |
| CN114671810B (zh) * | 2022-03-21 | 2024-03-22 | 济南鸿湾生物技术有限公司 | 一种咪唑苯脲的制备方法 |
| CN115611768B (zh) * | 2022-11-14 | 2024-03-05 | 郑州大学 | 一种3,4-二氯苯腈的合成方法 |
| CN118724764B (zh) * | 2024-06-07 | 2025-11-18 | 绍兴文理学院 | 一种芳基伯磺酰胺类化合物的制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4766131A (en) * | 1980-10-17 | 1988-08-23 | Pennwalt Corporation | 2-amino (or hydroxy) phenethyl-1,2,3,4-tetrahydroisoquinolines as analgesics |
| IL162310A0 (en) * | 2001-12-19 | 2005-11-20 | Lundbeck & Co As H | 3,4-Dihydro-1h-isoquinoloin-2-yl-derivatives |
| ATE459618T1 (de) * | 2004-04-29 | 2010-03-15 | Aventis Pharma Inc | 3-piperidinylisochroman-5-ole als dopaminagonisten |
| EP2125741A1 (en) * | 2007-03-01 | 2009-12-02 | Janssen Pharmaceutica, N.V. | Tetrahydroisoquinoline compounds as modulators of the histamine h3 receptor |
-
2015
- 2015-10-06 DK DK15775688.3T patent/DK3204359T3/da active
- 2015-10-06 ES ES15775688T patent/ES2821821T3/es active Active
- 2015-10-06 PT PT157756883T patent/PT3204359T/pt unknown
- 2015-10-06 HU HUE15775688A patent/HUE050664T2/hu unknown
- 2015-10-06 CN CN201580064005.3A patent/CN107001278B/zh not_active Expired - Fee Related
- 2015-10-06 JP JP2017518989A patent/JP6622299B2/ja active Active
- 2015-10-06 WO PCT/EP2015/073053 patent/WO2016055479A1/en not_active Ceased
- 2015-10-06 BR BR112017007123-1A patent/BR112017007123B1/pt not_active IP Right Cessation
- 2015-10-06 PL PL15775688.3T patent/PL3204359T3/pl unknown
- 2015-10-06 EP EP15775688.3A patent/EP3204359B1/en active Active
- 2015-10-06 HR HRP20201469TT patent/HRP20201469T1/hr unknown
- 2015-10-06 LT LTEP15775688.3T patent/LT3204359T/lt unknown
- 2015-10-06 CA CA2963951A patent/CA2963951C/en active Active
- 2015-10-06 EA EA201790785A patent/EA035544B1/ru not_active IP Right Cessation
- 2015-10-06 SI SI201531348T patent/SI3204359T1/sl unknown
- 2015-10-06 US US15/517,795 patent/US10105359B2/en active Active
- 2015-10-06 RS RS20201139A patent/RS60933B1/sr unknown
-
2020
- 2020-09-30 CY CY20201100923T patent/CY1123417T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016055479A1 (en) | 2016-04-14 |
| BR112017007123A2 (pt) | 2017-12-19 |
| PT3204359T (pt) | 2020-09-24 |
| EA035544B1 (ru) | 2020-07-03 |
| US20170304292A1 (en) | 2017-10-26 |
| EP3204359A1 (en) | 2017-08-16 |
| CN107001278B (zh) | 2020-11-24 |
| CN107001278A (zh) | 2017-08-01 |
| PL3204359T3 (pl) | 2021-03-22 |
| CY1123417T1 (el) | 2021-12-31 |
| CA2963951A1 (en) | 2016-04-14 |
| EP3204359B1 (en) | 2020-07-01 |
| DK3204359T3 (da) | 2020-09-14 |
| LT3204359T (lt) | 2020-10-12 |
| JP6622299B2 (ja) | 2019-12-18 |
| US10105359B2 (en) | 2018-10-23 |
| SI3204359T1 (sl) | 2020-10-30 |
| JP2017530185A (ja) | 2017-10-12 |
| EA201790785A1 (ru) | 2017-10-31 |
| HRP20201469T1 (hr) | 2020-12-11 |
| HUE050664T2 (hu) | 2020-12-28 |
| ES2821821T3 (es) | 2021-04-27 |
| CA2963951C (en) | 2023-02-28 |
| BR112017007123B1 (pt) | 2023-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2821821T3 (es) | Derivados de tetrahidroisoquinolina | |
| US9133122B2 (en) | Amide compounds, compositions and uses thereof | |
| CN109715613B (zh) | 杂环化合物 | |
| CN113214287B (zh) | Hpk1抑制剂及其使用方法 | |
| TW202229240A (zh) | 新穎化合物 | |
| JPWO2014077401A1 (ja) | 含窒素複素環化合物 | |
| TW201710255A (zh) | 雜環化合物 | |
| JPWO2017069173A1 (ja) | 複素環化合物 | |
| EP3790865A1 (en) | Phenyl substituted pyrazoles as modulators of roryt | |
| ES2960408T3 (es) | Compuesto heterocíclico y su uso como modulador alostérico positivo del receptor M1 muscarínico colinérgico | |
| WO2019189555A1 (ja) | 複素環化合物 | |
| ES2729490T3 (es) | Derivados de isoindolina | |
| AU2019229188B2 (en) | Substituted cyclohexyl compounds as NOP inhibitors | |
| BR112019026096A2 (pt) | composto, medicamento, métodos para modulação alostérica positiva do receptor muscarínico colinérgico m1 e para a profilaxia ou o tratamento de constipação, e, uso do composto | |
| RU2809257C2 (ru) | Новые гетероциклические соединения | |
| HK40057478B (zh) | Hpk1抑制剂及其使用方法 | |
| TW201341380A (zh) | 磺醯胺衍生物及其用途 | |
| HK40034295B (en) | Substituted cyclohexyl compounds as nop inhibitors | |
| HK40034295A (en) | Substituted cyclohexyl compounds as nop inhibitors |